Tatva Chintan Pharma Chem Limited Stock Price Today (NSE: TATVA)
Fundamental Score
Tatva Chintan Pharma Chem Limited Share Price Live NSE/BSE & Institutional Fundamental Analysis
Tatva Chintan Pharma Chem Limited share price today is ₹1176.40, up +0.00% on NSE/BSE as of 18 March 2026. Tatva Chintan Pharma Chem Limited (TATVA) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of ₹3.37K (Cr). The 52-week high for TATVA share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 189.69x, TATVA is currently trading above its industry average P/E of 29.20x. The company has a Return on Equity (ROE) of 0.78% and a debt-to-equity ratio of 0.11.
Tatva Chintan Pharma Chem Limited Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Tatva Chintan Pharma Chem Limited Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Tatva Chintan Pharma Chem Share Price: A Conservative Value Investor's Perspective
Specialty chemicals, unlike commodity chemicals, often command premium valuations due to their tailored functionalities and niche applications. However, a high degree of specialization doesn't automatically translate to a safe investment. This analysis examines the Tatva Chintan Pharma Chem share price, currently at ₹1144.0, through the lens of a conservative value investor prioritizing capital preservation. This is part of a broader 80-parameter fundamental audit overseen and verified by Sweta Mishra.
At first glance, the PE ratio of 189.69 raises a significant red flag. While high PE ratios can sometimes be justified by rapid growth, this needs to be coupled with robust profitability metrics. Tatva Chintan's Return on Capital Employed (ROCE) of 1.2% is alarmingly low. This suggests that the company is not efficiently generating returns from its invested capital. This low ROCE severely undermines any potential economic moat the company might possess. A company generating such low returns is unlikely to sustain any competitive advantage over the long term. Capital will likely migrate elsewhere, seeking higher returns.
Furthermore, when considering peer companies like
Amal, it's crucial to assess management quality and capital allocation skills. While this analysis cannot definitively comment on management quality without in-depth qualitative research, consistently low ROCE levels, such as observed in Tatva Chintan Pharma Chem, can be indicative of less-than-optimal capital deployment decisions. A higher ROCE would suggest that management is creating more value for the shareholders.In conclusion, from a conservative value investing perspective focused on capital safety, the current Tatva Chintan Pharma Chem share price appears to present a high degree of risk. The elevated PE ratio coupled with a very low ROCE suggests that the company may be significantly overvalued, leaving little margin of safety for potential investors. Further due diligence is warranted, paying close attention to the long-term sustainability of returns and competitive advantages.
Disclaimer: This analysis is for informational purposes only and does not constitute financial advice. The author holds no positions in the mentioned companies. Investment decisions should be based on individual circumstances and thorough research.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Tatva Chintan Pharma Chem Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TATVA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (17.54%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (1603.03%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (47.95%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.11)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (15.20x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (72.02%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (0.78%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (1.20%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 189.69x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-44.61% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-31.41% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-327.00 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 7.27%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Tatva Chintan Pharma Chem Limited Financial Statements
Comprehensive financial data for Tatva Chintan Pharma Chem Limited including income statement, balance sheet and cash flow
About TATVA (Tatva Chintan Pharma Chem Limited)
Tatva Chintan Pharma Chem Limited (TATVA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Specialty Chemicals sector with a current market capitalisation of ₹3.37K (Cr). Tatva Chintan Pharma Chem Limited has delivered a Return on Equity (ROE) of 0.78% and a ROCE of 1.20%. The debt-to-equity ratio stands at 0.11, reflecting the company's capital structure. Investors tracking TATVA share price can monitor key metrics including P/E ratio, promoter holding of 72.02%, and quarterly earnings growth.
Company Details
Key Leadership
TATVA Share Price: Frequently Asked Questions
What is the current share price of Tatva Chintan Pharma Chem Limited (TATVA)?
As of 18 Mar 2026, 10:29 am IST, Tatva Chintan Pharma Chem Limited share price is ₹1176.40. The TATVA stock has a market capitalisation of ₹3.37K (Cr) on NSE/BSE.
Is TATVA share price Overvalued or Undervalued?
TATVA share price is currently trading at a P/E ratio of 189.69x, compared to the industry average of 29.20x. Based on this relative valuation, the Tatva Chintan Pharma Chem Limited stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of TATVA share price?
The 52-week high of TATVA share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Tatva Chintan Pharma Chem Limited share price?
Key factors influencing TATVA share price include quarterly earnings growth (Sales Growth: 47.95%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Tatva Chintan Pharma Chem Limited a good stock for long-term investment?
Tatva Chintan Pharma Chem Limited shows a 5-year Profit Growth of -31.41% and an ROE of 0.78%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.11 before investing in TATVA shares.
How does Tatva Chintan Pharma Chem Limited compare with its industry peers?
Tatva Chintan Pharma Chem Limited competes with major peers in the Specialty Chemicals. Investors should compare TATVA share price P/E of 189.69x and ROE of 0.78% against the industry averages to determine competitive standing.
What is the P/E ratio of TATVA and what does it mean?
TATVA share price has a P/E ratio of 189.69x compared to the industry average of 29.20x. Investors pay ₹190 for every ₹1 of annual earnings.
How is TATVA performing according to Bull Run's analysis?
TATVA has a Bull Run fundamental score of 37.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does TATVA belong to?
TATVA operates in the Specialty Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Tatva Chintan Pharma Chem Limited share price.
What is Return on Equity (ROE) and why is it important for TATVA?
TATVA has an ROE of 0.78%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Tatva Chintan Pharma Chem Limited generates profits from shareholders capital.
How is TATVA debt-to-equity ratio and what does it indicate?
TATVA has a debt-to-equity ratio of 0.11, which indicates conservative financing with low financial risk.
What is TATVA dividend yield and is it a good dividend stock?
TATVA offers a dividend yield of 0.07%, meaning you receive ₹0.07 annual dividend for every ₹100 invested in Tatva Chintan Pharma Chem Limited shares.
How has TATVA share price grown over the past 5 years?
TATVA has achieved 5-year growth rates of: Sales Growth 7.77%, Profit Growth -31.41%, and EPS Growth -44.61%.
What is the promoter holding in TATVA and why does it matter?
Promoters hold 72.02% of TATVA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Tatva Chintan Pharma Chem Limited.
What is TATVA market capitalisation category?
TATVA has a market capitalisation of ₹3365 crores, placing it in the Small-cap category.
How volatile is TATVA stock?
TATVA has a beta of N/A. A beta > 1 suggests the Tatva Chintan Pharma Chem Limited stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is TATVA operating profit margin trend?
TATVA has a 5-year average Operating Profit Margin (OPM) of 17.54%, indicating the company's operational efficiency.
How is TATVA quarterly performance?
Recent quarterly performance shows Tatva Chintan Pharma Chem Limited YoY Sales Growth of 47.95% and YoY Profit Growth of 1603.03%.
What is the institutional holding pattern in TATVA?
TATVA has FII holding of 3.40% and DII holding of 3.87%. Significant institutional holding often suggests professional confidence in the Tatva Chintan Pharma Chem Limited stock.